Dear Susan,

Thank you for your email dated 2nd November 2015, and copied below for ease of reference, regarding the breast screening age-extension trial. I apologise again for the delay in replying.

It is important to clarify that CRUK is not a funder of the trial itself and thus the questions you raise in your email below do not apply. The Principal Investigator for this trial is Julietta Patnick and the trial is supported by Public Health England and the NHS Breast Screening Programme.

CRUK does provide programme grant support to Professor Dame Valerie Beral at the University of Oxford whose team does undertake work on the trial as part of a broad range of activities related to cancer epidemiology work. However, we do not provide funding for the trial itself. The ISRCTN link which lists CRUK as a funder is incorrect.

Yours sincerely
Harpal Kumar

Harpal S Kumar
Chief Executive Officer,
Cancer Research UK

Angel Building,
407 St John Street,
London EC1V 4AD
Tel: +44 (0) 20 3469 8468/9
E-mail: harpal.kumar@cancer.org.uk
www.cancerresearchuk.org
Dear Harpal Kumar

I understand that CRUK is a funder of the nationwide cluster-randomised trial of extending the NHS breast screening age range in England, [http://www.isrctn.com/ISRCTN33292440](http://www.isrctn.com/ISRCTN33292440) a cluster RCT without explicit consent running since 2009 and which has undergone major revision in the light of the 2012 Marmot report finding of equipoise and our submissions.

Healthwatch-UK (a charity “for science and integrity in medicine”) has concerns about the science and ethics – all detailed on its website starting with [http://www.healthwatch-uk.org/news/44-concerns-over-age-extension-trial-of-mammography-screening-part-1.html](http://www.healthwatch-uk.org/news/44-concerns-over-age-extension-trial-of-mammography-screening-part-1.html). You will see that it took an FOI request to obtain a copy of the initial protocol v1 and there are grave scientific concerns about its credibility, especially considering the trial referred to “so-called” overdiagnosis from the start (which we last had cause to discuss in the light of the CRUK handling of the Marmot press conference).

I would be very grateful to understand CRUKs role in supporting this trial:

a) What were the CRUK review and governance processes when this trial started?
b) Would CRUK have expected such an RCT that it funded to satisfy ICH-GCP?
c) As a co-funder, how was the CRUK informed, involved with, and satisfied by, (a) the initial peer review process of protocol v1, and (b) the change of research question to protocol v3?
d) How much funding have you supplied and will continue to supply?

With best wishes

Susan Bewley  MA MD FRCOG
Professor of Complex Obstetrics, KCL
c/o Division of Women’s Health KCL
Women’s Health Academic Centre, King’s Health Partners (KHP)
10th floor North Wing, St Thomas’ Hospital
Westminster Bridge Rd
London SE1 7EH

Mob: 07984 907 548
Tel: 020 7188 4138
Fax: 020 7620 1227
Skype name: sjbewley

**Out now!**  ABC of Domestic and Sexual Violence [Click here](#) to read more and buy a copy.

Websites: [http://kcl.academia.edu/susanbewley](http://kcl.academia.edu/susanbewley)
[http://www.kcl.ac.uk/schools/medicine/research/hscr/staff/bewley.html](http://www.kcl.ac.uk/schools/medicine/research/hscr/staff/bewley.html)
[http://www.kcl.ac.uk/medicine/research/divisions/wh/index.aspx](http://www.kcl.ac.uk/medicine/research/divisions/wh/index.aspx)
NOTICE AND DISCLAIMER
This e-mail (including any attachments) is intended for the above-named person(s). If you are not the intended recipient, notify the sender immediately, delete this email from your system and do not disclose or use for any purpose.

We may monitor all incoming and outgoing emails in line with current legislation. We have taken steps to ensure that this email and attachments are free from any virus, but it remains your responsibility to ensure that viruses do not adversely affect you.

Cancer Research UK
Registered charity in England and Wales (1089464), Scotland (SC041666) and the Isle of Man (1103)
A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F).
Registered Office Address: Angel Building, 407 St John Street, London EC1V 4AD.